OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting
04 nov. 2015 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that new data comparing the anti-tumor immune response of its anti-DLL4/VEGF bispecific...
OncoMed Pharmaceuticals to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015
29 oct. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology...
OncoMed Announces Multiple Abstracts Accepted for Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
27 oct. 2015 11h12 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that data related to three of its clinical-stage programs will be presented at the...
OncoMed to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
29 sept. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference
16 sept. 2015 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Announces Presentation of Tarextumab Small Cell Lung Cancer Data at the 16th World Conference on Lung Cancer
09 sept. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
New Prognostic and Prevalence Data Highlight Role of Notch3 Overexpression
in Small Cell Lung Cancer
Encouraging Efficacy Results Updated from Phase 1b Clinical Trial of Tarextumab
DENVER,...
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic Cancer
31 août 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 31, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
Notch3 Biomarker Results and Updated Data From OncoMed's Phase 1b/2 PINNACLE Clinical Trial Accepted for Presentation at the 16th World Conference on Lung Cancer
27 août 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3,...
OncoMed Pharmaceuticals Announces Second Quarter 2015 Financial Results and Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data
10 août 2015 16h16 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) today reported financial results for the quarter ended June 30, 2015 and provided an update on...
OncoMed Pharmaceuticals to Report Second Quarter 2015 Financial Results on Monday, August 10, 2015
05 août 2015 16h18 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics,...